Aberdeen Village: Monthly Drug Review Lapses - KS
That observation, recorded at Aberdeen Village on February 9, 2026, sits at the center of a federal inspection finding that the facility had been administering Quetiapine, sold under the brand name Seroquel, to the resident identified in inspection records as Resident 20, without a Centers for Medicare and Medicaid Services approved indication for the drug. The facility could not produce a documented rationale for the prescription when inspectors asked for one on February 10.
Resident 20 carries diagnoses of Alzheimer's disease, a prior stroke, insomnia, and major depressive disorder. A cognitive assessment completed in January 2026 gave her a score of four on the Brief Interview for Mental Status scale, which places her in the range of severe cognitive impairment. Despite that impairment, her records show she was independent with meals, oral hygiene, toileting, bathing, dressing, transfers, and bed mobility at the time of the assessment. The same assessment noted no behaviors during the observed period.
She arrived at Aberdeen Village on April 15, 2025, already on the medication. A physician order dated a month later, May 15, renewed her prescription for 12.5 milligrams of Quetiapine Fumarate by mouth once daily, listing the indication as "unspecified dementia with psychotic disturbances." Her care plan, initiated April 28, documented that she had behaviors of resisting care and yelling out, and noted she was taking Quetiapine in connection with those behaviors. But the care plan contained no psychiatric indications for the drug. And her electronic medical records contained no behavioral monitoring tied to the antipsychotic at all.
That gap matters. Antipsychotic medications carry serious risks for elderly patients with dementia, a fact the facility's own records acknowledged. A care assessment completed December 22, 2025 noted that Resident 20 was at risk for adverse effects related to her Seroquel. The care plan instructed staff to monitor her for medication side effects. Whether anyone was doing so in any systematic way, the records did not show.
The facility's consultant pharmacist had been flagging the prescription. A review of pharmacist recommendation forms covering May 2025 through February 2026 showed that on December 10, 2025, the consulting pharmacist recommended a gradual dose reduction to bring Resident 20 to the lowest possible effective dose. The medical provider declined. The reason documented on the form: risk of decompensation, meaning a concern that reducing the dose could worsen her symptoms or behaviors. That is a legitimate clinical consideration. What the pharmacist's recommendations did not address, across the entire review period, was whether the antipsychotic had an appropriate CMS-approved indication in the first place.
On the morning of February 10, the consultant identified in inspection records as Consultant GG told inspectors that Resident 20 had come to the facility on the antipsychotic, and that her family representative had refused to allow changes or discontinuation of the medication. The consultant said the resident needed the drug for dementia-related hallucinations and delusions.
Later that afternoon, two nursing staff members told inspectors something different. Licensed Nurse G said antipsychotic medication was not indicated for dementia treatment and that the medication required a psychiatric reason or diagnosis. Administrative Nurse D said she had spoken with Resident 20's representative multiple times about changing the medication's indications, and the representative had refused each time. She acknowledged that dementia was not an indication for the medication but said Resident 20 had arrived at the facility already on it, with a dementia diagnosis.
Those two conversations, separated by sixteen minutes, describe a facility that understood the problem and had not solved it. The staff knew the indication was inadequate. They knew the family had resisted changes. And when inspectors asked for a documented rationale for the continued use of the drug without an appropriate indication, the facility could not provide one.
The clinical and regulatory question here is specific. CMS maintains a list of approved indications for antipsychotic use in nursing home residents. Dementia alone is not among them. The approved indications include conditions such as schizophrenia, schizophrenia-related disorders, Tourette's disorder, Huntington's disease, and documented, clinically significant behavioral symptoms that have not responded to non-pharmacological approaches. A physician who declines a pharmacist's dose reduction recommendation can do so, but the underlying indication for the drug still has to hold up. At Aberdeen Village, the indication listed in the physician order, "unspecified dementia with psychotic disturbances," was not documented with the supporting behavioral evidence that would give it weight. The care plan referenced resisting care and yelling out, but the medical records contained no behavioral monitoring to substantiate an ongoing pattern, and no psychiatric diagnosis was documented to anchor the prescription.
The family's role in this situation adds a layer that the inspection record captures but does not fully resolve. A resident's representative can decline medication changes, and facilities must navigate that reality. But the representative's refusal to allow discontinuation does not relieve the facility of its obligation to ensure the prescription rests on an approved and documented clinical foundation. Administrative Nurse D's account suggests the facility treated the family's resistance as the end of the conversation. The inspection finding suggests it should have been the beginning of a more formal process to document, justify, or change the prescription.
Aberdeen Village reported a census of 54 residents at the time of the inspection. Inspectors reviewed records for 19 of them, with 5 specifically examined for unnecessary medication concerns. The antipsychotic finding applied to Resident 20. The harm level was assessed as minimal harm or potential for actual harm, the lower end of the federal scale, though the classification reflects the absence of documented injury rather than the absence of risk. Quetiapine carries a black box warning for elderly patients with dementia-related psychosis, the most serious warning the Food and Drug Administration issues, noting an increased risk of death in that population.
The facility's own drug regimen review policy, revised in April 2025, commits the facility to monthly medication reviews in collaboration with a licensed pharmacist to identify irregularities and ensure safe medication practices. The pharmacist had identified an irregularity. The recommendation had been declined. And the underlying question about whether the prescription had a valid approved indication went unresolved for months.
On the morning inspectors watched her, Resident 20 was calm. She was engaged. She showed no behaviors. She had been taking a powerful psychiatric medication every day since at least mid-April 2025, with no behavioral monitoring in her chart, no documented psychiatric indication in her care plan, and no rationale her facility could hand over when someone finally asked for one.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Aberdeen Village from 2026-02-10 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: August 5, 2026 · Our methodology
ABERDEEN VILLAGE in OLATHE, KS was cited for violations during a health inspection on February 10, 2026.
The facility could not produce a documented rationale for the prescription when inspectors asked for one on February 10.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.